Regenerative treatments — an honest evaluation

Our approach to regenerative treatments

Regenerative therapies are the area where families most often arrive with hope, pressure, conflicting information and — sometimes — overpromised expectations. My principle here is the same as in every other area of our practice: precision-first. If the work-up identifies an underlying genetic, metabolic, structural or immune cause we can act on, that comes first; in many cases that single step changes the trajectory more than anything we could add on top. If conventional, evidence-based rehabilitation has not yet been optimised — intensity, model, goals — we optimise that first, because the literature is clear that intensive, goal-directed rehabilitation done well outperforms anything layered on top of generic care.

Only then do we ask whether regenerative and neuromodulation options have a real, child-specific place. The questions we ask together are practical, not promotional: what does the current literature actually show for this child's condition? What is the realistic best-case improvement, and how would we know if it happened? What are the side-effect, cost, time and emotional burdens? Are there alternatives that would deliver more for less? And — every time — is the proposed treatment offered within an appropriate regulatory and ethical framework, with full informed consent and Ministry of Health authorisation where it is required?

The picture we emphasise throughout these decisions is the combined intensive approach. Cell or exosome therapy alongside neuromodulation methods (photobiomodulation and others where appropriate) and intensive, goal-directed rehabilitation in the days and weeks around the intervention — that is the package we believe makes the most clinical difference, and the one the biology of brain plasticity supports. Delivered as separate, unsynchronised efforts, these techniques tend to disappoint; delivered as one integrated programme, they have given us our most meaningful clinical signals.

Cell therapies — stem cells

Stem-cell therapies in paediatric neurology draw from a number of different sources — umbilical-cord blood, umbilical-cord-derived mesenchymal stem cells, adipose-derived and bone-marrow-derived mesenchymal stem cells, among others. Each source has its own biology, its own evidence profile and its own indication picture; they are not interchangeable. The choice of source is not neutral and it is not made by family preference alone — it is shaped by the child's age, clinical picture, imaging findings, available product quality and regulatory framework.

The conditions in which we most often discuss cell therapies include cerebral palsy, the late sequelae of hypoxic-ischaemic encephalopathy and other perinatal brain injury, and selected genetic and structural disorders affecting brain development. The evidence base is strongest in younger children with milder-to-moderate involvement, where carefully designed trials have shown modest but real signals; the evidence weakens substantially in older children, in severe global brain involvement, and where the product or protocol is poorly characterised. We discuss every case individually and proceed only with full informed consent and the Republic of Türkiye Ministry of Health authorisation that any such treatment legally requires.

Exosome therapies — patient-tailored, research phase

Exosomes — extracellular vesicles derived from stem cells — are one of the most actively studied frontiers in regenerative neurology. The biological argument is compelling: vesicles carrying defined proteins, lipids and microRNAs that can cross the blood-brain barrier, especially when delivered intranasally, and modulate inflammation, plasticity and repair in target tissue.

What makes exosomes distinctive in clinical practice is that different cellular sources produce exosomes with intrinsically different molecular cargoes. That opens up the possibility of tailoring the source — and therefore the content — to the child's clinical picture. In practical terms, exosomes have a favourable side-effect profile, are relatively straightforward to administer, can produce a fast clinical signal, and allow individualised content selection.

The honest counterweight is that their scientific efficacy in paediatric neurology is still in the research phase. We apply exosome therapies in the framework of structured scientific studies and not as proven treatment, with very explicit honesty about what is and is not known. Where we use them, it is in carefully selected children, under appropriate authorisation, combined with neuromodulation and intensive rehabilitation, and with structured objective follow-up so that response is measured rather than assumed.

Photobiomodulation (PBM)

Photobiomodulation — the use of red and near-infrared light, delivered transcranially or intranasally — has a strong basic-science rationale: enhancement of mitochondrial cytochrome-c-oxidase activity, modulation of neuroinflammation, and effects on neuronal energetics and connectivity. Preclinical work is encouraging; small clinical studies in conditions including cerebral palsy, traumatic brain injury, autism, cognitive impairment after hypoxic injury and selected neurodevelopmental disorders have shown early but consistent signals.

In our practice, photobiomodulation is most often used in selected children with cerebral palsy, late sequelae of perinatal brain injury, autism with selected indications, and selected drug-resistant epilepsies — as part of an integrated plan, not as a stand-alone intervention. It pairs naturally with cell and exosome therapies in the combined approach we emphasise, and with intensive rehabilitation in the period around the intervention.

The clinical evidence base is still maturing. We are honest with families about what photobiomodulation can and cannot deliver, set explicit response thresholds at baseline, and measure outcomes with the same scales we use elsewhere — so we know what is working and what is not.

Combined intensive approach — why we do not deliver these in isolation

If there is a single message that defines our regenerative practice, it is this: none of these techniques work best on their own. Brain plasticity does not respond to a single biological signal delivered in isolation; it responds to the right signal delivered in the right context, with the right repetitive, goal-directed practice in the days and weeks that follow.

The combined approach we emphasise links three elements. First, the regenerative intervention itself — cell therapy or exosome therapy, with the source and protocol selected for this child. Second, neuromodulation methods, most often photobiomodulation, that prime the brain for the structural and connectivity changes the regenerative signal is encouraging. Third, intensive, goal-directed rehabilitation — physiotherapy, occupational therapy, speech and language therapy, and sensory work — delivered at an unusually high intensity in the period around the intervention.

This is not a packaged protocol sold as a course; it is a coordinated programme planned with you, your child's existing therapy team, and the specialists who deliver each part. It is more demanding than a single injection or a single therapy block, but it is also where the literature on neuroplasticity, the biology of regenerative signals, and our own clinical experience all point.

We also keep an open, evidence-led eye beyond Western biomedicine. Selected elements from Russian neurorehabilitation schools, Indian Ayurvedic medicine and Traditional Chinese Medicine have, in specific situations, a research base that justifies considering them alongside the conventional plan — particular acupuncture techniques in motor recovery, defined herbal preparations with reproducible pharmacology, and structured rehabilitation methodologies developed outside North American and European centres. We do not adopt any of these by tradition or popularity alone; we incorporate the elements that have credible evidence behind them, alongside the rest of the plan, and we are explicit with families about which strands sit on stronger evidence and which sit on emerging or weaker evidence.

When we say no — and why

Saying no is part of the same care. There are children, families and presentations where regenerative therapy is not the right step — at all, or not yet. We will say no when there is severe global brain involvement with no realistic target the biology can act on; when an unresolved orthopaedic, epilepsy or feeding problem should come first; when expectations are unrealistic given the literature; when the family is being asked to fund a treatment whose product, protocol or provider does not meet appropriate quality standards; and when the timing — the child's age, condition, or therapy phase — makes the intervention less likely to help and more likely to disappoint.

We are also vigilant about the red flags that come from outside our practice. Treatments offered without informed consent or proper authorisation; products of uncertain origin or quality; clinics that promise cure or imply guaranteed improvement; protocols that bypass the rehabilitation context in which regenerative signals can actually be used. When families come to us with these offers, we explain, in detail, why we would not recommend going ahead — and what we would do instead.

Saying "not yet" or "not for this child" with honest reasoning protects families from disappointment, from financial harm and, occasionally, from real medical risk. It is, in its own way, the same evidence-led care that goes into every other decision we make.